Patient-reported outcomes (PROs) in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in the phase 1b/2 EV-103 Cohort K study.

被引：0

作者：

Milowsky, Matthew I.

O'Donnell, Peter H.

Hoimes, Christopher J.

Petrylak, Daniel P.

Flaig, Thomas W.

Moon, Helen H.

Friedlander, Terence W.

Mar, Nataliya

McKay, Rana R.

Srinivas, Sandy

Gravis, Gwenaelle

Ramamurthy, Chethan

Bupathi, Manojkumar

Bracarda, Sergio

Wright, Phoebe

Carret, Anne-Sophie

Yu, Yao

Matsuda, Tara

Kataria, Ritesh S.

Rosenberg, Jonathan E.

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Duke Univ, Duke Canc Inst, Durham, NC USA

[4] Yale Canc Ctr, New Haven, CT USA

[5] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA

[6] Kaiser Permanente Southern Calif Reg, Hematol Oncol, Riverside, CA USA

[7] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

[8] Univ Calif Irvine, Orange, CA 92668 USA

[9] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[10] Stanford Univ, Med Ctr, Stanford, CA 94305 USA

[11] Inst Paoli Calmettes, Marseille, France

[12] Univ Texas Hlth, MD Anderson Canc Ctr, San Antonio, TX USA

[13] Rocky Mt Canc Ctr, Littleton, CO USA

[14] Azienda Osped Santa Maria, Terni, Italy

[15] Seagen Inc, Bothell, WA USA

[16] Astellas Pharma Inc, Northbrook, IL USA

[17] Merck & Co Inc, Rahway, NJ USA

[18] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[19] Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

439

引用

页数：1